BBLG — Bone Biologics Corporation
Bone Biologics Corporation, a medical device enterprise, specializes in fostering bone regeneration for spinal fusion, leveraging its advanced recombinant human protein technology. Its flagship product, NELL-1/DBX, is a unique combination of an osteostimulative recombinant protein designed for precise, targeted control over bone regrowth. The company is currently advancing the NELL-1/DBX Fusion Device, intended for spinal fusion interventions in skeletally mature individuals experiencing single-level degenerative disc disease within the L4-S1 spinal segments. This versatile platform technology also holds the potential to deliver superior outcomes across a wide spectrum of surgical specialties, including spinal, various orthopedic fields, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Bone Biologics holds a licensing agreement with the UCLA Technology Development Group, which authorizes the development and commercialization of NELL-1 for its spinal fusion applications. The firm was established in 2004 and is based in Burlington, Massachusetts.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Capital Market
- Employees: 2
- Website: https://www.bonebiologics.com
Latest SEC filings for BBLG
- 10-Q — 2026-08-14
- 424B3 — 2026-07-24
- 8-K — 2026-07-23
- S-3 — 2026-07-17
- 8-K — 2026-07-16
- 8-K — 2026-07-09
- 10-Q — 2026-05-14
- 8-K — 2026-03-13
- 424B5 — 2026-03-13
- 10-K — 2026-03-02
Educational tool only — not investment advice.